Odonate Therapeutics Inc (ODT) CEO Kevin C. Tang Acquires 10,235 Shares

Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang bought 10,235 shares of the business’s stock in a transaction on Monday, October 29th. The shares were acquired at an average cost of $14.98 per share, with a total value of $153,320.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of NASDAQ ODT traded down $0.45 during trading on Tuesday, reaching $14.52. The stock had a trading volume of 34,725 shares, compared to its average volume of 53,676. Odonate Therapeutics Inc has a fifty-two week low of $14.06 and a fifty-two week high of $32.00. The stock has a market capitalization of $408.59 million and a PE ratio of -6.29.

Odonate Therapeutics (NASDAQ:ODT) last issued its quarterly earnings data on Tuesday, October 23rd. The company reported ($0.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.02). As a group, analysts expect that Odonate Therapeutics Inc will post -3.49 EPS for the current year.



Several hedge funds and other institutional investors have recently modified their holdings of the company. Northern Trust Corp grew its stake in shares of Odonate Therapeutics by 6.0% in the second quarter. Northern Trust Corp now owns 74,510 shares of the company’s stock valued at $1,645,000 after buying an additional 4,204 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Odonate Therapeutics by 19.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 34,137 shares of the company’s stock valued at $754,000 after buying an additional 5,601 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Odonate Therapeutics in the first quarter valued at $128,000. Alps Advisors Inc. grew its stake in shares of Odonate Therapeutics by 21.9% in the third quarter. Alps Advisors Inc. now owns 47,584 shares of the company’s stock valued at $924,000 after buying an additional 8,562 shares in the last quarter. Finally, California State Teachers Retirement System acquired a new stake in shares of Odonate Therapeutics in the first quarter valued at $218,000. 86.90% of the stock is owned by institutional investors and hedge funds.

Separately, Zacks Investment Research cut Odonate Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 5th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $31.00.

About Odonate Therapeutics

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.

Featured Story: Using the New Google Finance Tool

Insider Buying and Selling by Quarter for Odonate Therapeutics (NASDAQ:ODT)

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply